The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
in that first study where we just looked at rapalogs to enhance flu vaccine response we noticed in a clinical trial you always collect adverse events reported by people and we noticed that the people who were getting the amter the rapalog were reporting fewer respiratory tract infection as adverse events and they weren't flu they were just all common respiratory tract infections
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
unless those old mice got rapamycin if they got six weeks of rapamycin uh they were a hundred percent effective at responding to the vaccine so at least for that measure of immune function rapamycin fully restored the immune system back to that of a youthful immune system
if the mice got 6 weeks of rap ayon treatment before the vaccine they were then 100% protected these are old mice they're now almost 28 months old so this is sort of an amazing uh demonstration of immune Rejuvenation in an aged mammal
that was also demonstrated by Joan manik and Lloyd klickstein six years later using everol it improves that's right in humans it also improves vaccine responses on some circumstances to influen in vaccination in humans
the same year that our lifespan paper appeared there was another paper where rap also from Michigan though not my lab at all in which they gave Rapa M to some old mice and shown that their influenza vaccine response was terrific if they'd had Rapa what rap mice and appears to do in their model is increases the production of B cells from the bone marrow so the mice would respond to influenza vaccine and then they were exposed to live virus and they surviv whereas the UN untreated controls did not survive
in some circumstances at least it's actually imuno boosting and that was also demonstrated by Joan manik and Lloyd clickstein six years later using everol of us it improves that's right in humans it also improves vaccine responses on some circumstances to influence in vaccination in humans
in humans it also improves vaccine responses on some circumstances to influence in vaccination in humans
I I like those papers. I I think there's definitely a nugget of truth in there and I think it can protect from respiratory infections if used correctly.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.